Published in Korean J Intern Med on December 28, 2015
Trial of High-Dose Rifampin in Patients With TB (HIRIF) | NCT01408914
Study of Daily Rifapentine for Pulmonary Tuberculosis | NCT00814671
Phase 2a EBA Trial of AZD5847 | NCT01516203
Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB (Opti-Q) | NCT01918397
Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations. Ann Lab Med (2017) 0.75
Clinical significance of smear positivity for acid-fast bacilli after ≥5 months of treatment in patients with drug-susceptible pulmonary tuberculosis. Medicine (Baltimore) (2016) 0.75
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J (2011) 8.96
Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med (2012) 6.73
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet (2012) 6.70
Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med (2012) 5.87
The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med (2009) 5.78
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (2009) 5.30
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med (2014) 5.23
Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med (2010) 5.01
Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med (2014) 4.95
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med (2012) 4.69
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med (2003) 4.67
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med (2003) 4.36
Totally drug-resistant tuberculosis in India. Clin Infect Dis (2011) 4.31
The action of antituberculosis drugs in short-course chemotherapy. Tubercle (1985) 3.69
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med (2004) 3.45
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med (2008) 3.01
A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J (2014) 2.75
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis (2014) 2.68
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J (2012) 2.61
Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis (2010) 2.61
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med (2015) 2.48
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med (2014) 2.42
A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med (2014) 2.39
Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother (2008) 2.33
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother (2012) 2.26
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis (2014) 2.18
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J (2012) 2.17
The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med (2005) 2.06
Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med (2014) 1.98
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother (2010) 1.89
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. Am J Respir Crit Care Med (2009) 1.79
Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother (2012) 1.75
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med (2015) 1.73
Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis (2013) 1.69
Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One (2012) 1.69
Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis (2011) 1.67
Global epidemiology of tuberculosis. Semin Respir Crit Care Med (2013) 1.66
Targeting persisters for tuberculosis control. Antimicrob Agents Chemother (2012) 1.65
The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis (2012) 1.61
Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J (2012) 1.54
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis (2012) 1.53
Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother (2012) 1.49
Fluoroquinolone resistance in Mycobacterium tuberculosis. What have we learnt? Int J Tuberc Lung Dis (2014) 1.47
Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis (2014) 1.37
Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2014) 1.36
Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China. Int J Antimicrob Agents (2013) 1.34
Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One (2014) 1.32
Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis (2007) 1.30
Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis (2012) 1.29
The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med (2005) 1.28
In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother (2010) 1.25
Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One (2013) 1.24
Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis (2012) 1.23
Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med (2013) 1.20
Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis (2013) 1.17
Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother (2012) 1.17
World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis (2012) 1.15
WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother (2013) 1.13
Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One (2014) 1.13
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. Eur Respir J (2015) 1.13
Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 1.12
Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. Respirology (2013) 1.09
Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis (2010) 1.08
The tuberculosis drug discovery and development pipeline and emerging drug targets. Cold Spring Harb Perspect Med (2015) 1.05
Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One (2013) 1.04
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr (2012) 1.04
Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother (2013) 1.03
Multidrug-resistant tuberculosis around the world: what progress has been made? Eur Respir J (2014) 1.01
Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol (2006) 1.01
Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis (2015) 0.97
TB and HIV Therapeutics: Pharmacology Research Priorities. AIDS Res Treat (2012) 0.94
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob Agents Chemother (2008) 0.94
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother (2015) 0.91
Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother (2014) 0.91
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid. Eur Respir J (2015) 0.91
Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. Int J Infect Dis (2015) 0.91
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. Int J Tuberc Lung Dis (2014) 0.88
Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis. Int J Tuberc Lung Dis (2012) 0.88
Emerging drugs for the treatment of tuberculosis. Expert Opin Emerg Drugs (2010) 0.88
Novel drugs against tuberculosis: a clinician's perspective. Eur Respir J (2014) 0.87
Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Chemother (2009) 0.86
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother (2014) 0.86
Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro. Biol Pharm Bull (2014) 0.85
Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India. Clin Infect Dis (2014) 0.85
Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerg Infect Dis (2015) 0.84
Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study. J Antimicrob Chemother (2014) 0.84
Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf (2002) 0.83
Short-course chemotherapy for tuberculosis. Lancet (1976) 0.82
Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother (2012) 0.82
Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model. Antimicrob Agents Chemother (2014) 0.81
Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother (2013) 0.81
Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother (2014) 0.81
Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob Agents Chemother (2013) 0.79
Utility of propidium monoazide viability assay as a biomarker for a tuberculosis disease. Tuberculosis (Edinb) (2014) 0.79
Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation. Int J Pharm (2012) 0.78
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother (2009) 2.47
Diagnosis and treatment of nontuberculous mycobacterial pulmonary diseases: a Korean perspective. J Korean Med Sci (2005) 2.15
Increasing Recovery of Nontuberculous Mycobacteria from Respiratory Specimens over a 10-Year Period in a Tertiary Referral Hospital in South Korea. Tuberc Respir Dis (Seoul) (2013) 1.31
Rapid diagnosis of tuberculosis and multidrug resistance using a MGIT 960 system. Ann Lab Med (2012) 1.13
Diagnosis of pulmonary tuberculosis and nontuberculous mycobacterial lung disease in Korea. Tuberc Respir Dis (Seoul) (2014) 1.01
Report of a Korean patient with cystic fibrosis, carrying Q98R and Q220X mutations in the CFTR gene. J Korean Med Sci (2006) 0.97
Risk factors for death during pulmonary tuberculosis treatment in Korea: a multicenter retrospective cohort study. J Korean Med Sci (2014) 0.92
The drug resistance profile of Mycobacterium abscessus group strains from Korea. Ann Lab Med (2013) 0.91
Chest radiographic findings in primary pulmonary tuberculosis: observations from high school outbreaks. Korean J Radiol (2010) 0.90
Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives. Tuberc Respir Dis (Seoul) (2016) 0.89
Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients. J Crit Care (2013) 0.87
Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci (2004) 0.85
QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment. PLoS One (2015) 0.84
Factors that Predict Negative Results of QuantiFERON-TB Gold In-Tube Test in Patients with Culture-Confirmed Tuberculosis: A Multicenter Retrospective Cohort Study. PLoS One (2015) 0.82
Clinical Utility of Additional Measurement of Total Lung Capacity in Diagnosing Obstructive Lung Disease in Subjects With Restrictive Pattern of Spirometry. Respir Care (2016) 0.81
Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium simiae: The First Reported Case in South Korea. Tuberc Respir Dis (Seoul) (2015) 0.78
Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. Int J Chron Obstruct Pulmon Dis (2015) 0.78
A case of pleural paragonimiasis confused with tuberculous pleurisy. Tuberc Respir Dis (Seoul) (2014) 0.77
The First Korean Case of Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium abscessus Subspecies bolletii in a Patient with Bronchiectasis. Tuberc Respir Dis (Seoul) (2014) 0.77
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response. J Antimicrob Chemother (2009) 0.77
Changes in the flow-volume curve according to the degree of stenosis in patients with unilateral main bronchial stenosis. Clin Exp Otorhinolaryngol (2015) 0.75
Down-Regulation of Serum High-Mobility Group Box 1 Protein in Patients with Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease. Tuberc Respir Dis (Seoul) (2017) 0.75
Progression of Tuberculous Pleurisy: From a Lymphocyte-Predominant Free-Flowing Effusion to a Neutrophil-Predominant Loculated Effusion. Tuberc Respir Dis (Seoul) (2016) 0.75
Association of ISMav6 with the Pattern of Antibiotic Resistance in Korean Mycobacterium avium Clinical Isolates but No Relevance between Their Genotypes and Clinical Features. PLoS One (2016) 0.75
Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium shinjukuense: The First Reported Case in Korea. Tuberc Respir Dis (Seoul) (2015) 0.75
Mycobacterium abscessus Lung Disease in a Patient with Kartagener Syndrome. Tuberc Respir Dis (Seoul) (2014) 0.75
Isolated Endobronchial Mycobacterium avium Disease Associated with Lobar Atelectasis in an Immunocompetent Young Adult: A Case Report and Literature Review. Tuberc Respir Dis (Seoul) (2015) 0.75
Airflow limitation severity and post-operative pulmonary complications following extra-pulmonary surgery in COPD patients. Respirology (2017) 0.75